Navigation Links
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Date:5/20/2008

-- Phase 1 RDEA119 data expected in second half of 2008 -- -- Presentation at the Seventh Annual JMP Securities Research Conference on May 21st canceled; webcast of corporate update scheduled during Ardea's

Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT --

SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating potent activity in mouse models of colitis. An oral presentation of the data was given at Digestive Disease Week (DDW) 2008 in San Diego, California.

The MEK1/2 pathway is important in cell cycle regulation in inflammatory bowel disease, including ulcerative colitis and Crohn's disease. RDEA119 was shown to reduce damage to colonic tissue in two different mouse models of colitis, murine trinitrobenzene sulfonic acid (TNBS) colitis model and murine dextran sulfate sodium (DSS) colitis model. The beneficial effect observed equaled or exceeded that of sulfasalazine (Azulfidine(R)), a therapy commonly used for acute and maintenance treatment of ulcerative colitis.

"Despite the existing treatments, there are still significant unmet medical needs for inflammatory bowel disease. Blocking the MEK1/2 pathway appears to be a promising strategy in the ongoing search for a new generation of therapies aimed to treat ulcerative colitis and Crohn's disease," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "These data further support the potential use of orally administered MEK inhibitors, such as RDEA119, for the treatment of inflammatory diseases."

To support the development of RDEA119 in inflammatory diseases, a Phase
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
2. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
3. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Neurocrine Biosciences Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a website ... , will celebrate its first anniversary in August. The ... designed to enhance the body,s ability to produce nitric ... is made up of a variety of phytonutrients and ... been found to increase nitric oxide production ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
Breaking Medicine Technology:Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... Pfizer Inc,s (NYSE: PFE ) phase III ... CCR5-tropic,HIV-1, increased efficacy was shown as a result ... of the enhanced version of Monogram,s Trofile(TM),Assay., ...
... Oct. 26 Paratek Pharmaceuticals, Inc. today,announced positive ... PTK,0796, a first-in-class aminomethylcycline (AMC). The Phase 2 ... (IV) forms of PTK 0796 to,Zyvox(R) in the ... infections (cSSSIs). Paratek,s trial met its primary safety ...
Cached Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 As part ... School of Medicine at Mount Sinai have helped identify ... the risk of developing schizophrenia, in the largest genomic ... with 80,000 people. The findings, published online in Nature, ... schizophrenia, and could lead to new approaches to treating ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... used to treat moderate-to-severe allergic asthma appears to offer relief ... standard medications, new research suggests. The prescription drug -- ... U.S. Food and Drug Administration approval earlier this year for ... is taken at a high dose for a six-month period ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 For more ... and cold storage consumers with dynamic, specialized ... and customer satisfaction. Offering 50-70% less energy requirements ... process. This process is completed through a non-chemical ... technologies also provide a 4.2 Micron droplet. The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3
... pioneer and global market leader in acai, with certified ... nationwide from Whole Foods to Publix, Kroger and Safeway, ... false claims by acai scam campaigns and consumer watchdog ... locals for centuries, is a highly nutritious fruit scientifically ...
... in football as it hosts conference chaired by its medical director ... ... Gulf Breeze, FL (Vocus) March 27, 2009 -- The fourth annual ... Orthopaedics & Sports Medicine will attract top physicians, physical therapists ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... call at 10:30 a.m. Eastern Daylight Time (EDT) on ... fiscal year 2008 financial,results. , ...
... concentrating in areas with high doctor/patient ratios, experts say ... and urban areas of the United States may soon ... for underserved and aging populations, a new study warns. ... areas with already established medical communities, a trend that ...
... School of Medicine have been named Early Career Scientists ... Iannis Aifantis, Ph.D. associate professor of pathology, co-director of ... Institute and Jeremy S. Dasen Ph.D., assistant professor of ... among 50 of the nation,s top scientists being honored ...
... passed today by the Democratically-controlled Michigan House of ... pockets of personal injury lawyers at the expense ... Commerce."By repealing Michigan,s lawsuit abuse protections, the supporters ... becomes a lawsuit magnet," said Wendy Block, Director ...
Cached Medicine News:Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 2Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 3Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 2Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 3Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Midwest and Northeast May Face Surgeon Shortage 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 3